Navigation Links
Pharsight Announces 1-For-3 Reverse Stock Split
Date:11/13/2007

MOUNTAIN VIEW, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that its Board of Directors has approved a one- for-three reverse split of the Company's stock, to take effect at 5:00 p.m., Eastern Time today, November 13, 2007. Pharsight's common stock will begin trading on a reverse split-adjusted basis under the same symbol "PHST.OB" beginning Wednesday, November 14, 2007.

At its annual meeting of stockholders held on August 8, 2007, Pharsight received stockholder approval of a proposal authorizing the Pharsight Board of Directors, in its discretion, to effect a reverse stock split of Pharsight's common stock, at a ratio within the range from one-for-three to one-for-six shares, at any time prior to the 2008 annual meeting of stockholders.

Today's announcement is consistent with the Company's stated plans to list its common stock on the Nasdaq Capital Market, which has a minimum bid price requirement of $4. The reverse split is intended to help meet this requirement, and the Company believes it meets all other criteria for listing. Pharsight filed an application to list its common stock on the Nasdaq Capital Market on September 18, 2007.

"We have been pursuing an opportunity to list Pharsight's common stock on the Nasdaq Capital Market by addressing all corporate reporting and listing requirements, and this reverse stock split should allow us to satisfy the final outstanding criteria of minimum bid price," said Shawn O'Connor, president, CEO and chairman of Pharsight. "By obtaining listing status on Nasdaq, we believe we can increase the investor audience able to invest in our common stock. We believe that this status coupled with the continued execution of our growth strategy may lead to an increase in our valuation, one that is more in-line with our long-term gr
'/>"/>

SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharsight Achieves First License Sale for Public-Source Database
2. Pharsight to Present at ROeS Seminar in Bern, Switzerland on September 10 & 11, 2007
3. Pharsight Expands Strategic Consulting Services Team
4. Pharsight Hosts Fourth Annual PKS User Group Meeting
5. Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007
6. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2015)... BRM) ("Biorem" or "the Company") today announced its results for the three ... financial statements and MD&A have been filed on SEDAR ( www.sedar.com ). ... 2014 , 2013 Revenue 3,968 , 5,121 ... 1,703 , 2,231 , 5,866 Operating  expenses ... , 4,562 Ebitda* 92 , 418 , ...
(Date:4/29/2015)... 29, 2015 Cambrex Corporation (NYSE: CBM ) ... on Friday, May 1, 2015 before the market opens. ... will host a conference call to discuss the financial results. ... , Friday, May 1, 2015 at 8:30 a.m. ... for U.S.1-719-325-2454 for International  Passcode:  7993632 Dial-in Replay: ...
(Date:4/29/2015)... The leading Regenerative Veterinary Medicine Company, VetStem ... cell therapy has processed more than 11,000 samples. ... successful treatment for horses with potentially fatal injuries to ... worldwide exclusive license for adipose-derived (fat derived) stem cell ... treated in January 2004. Shortly after, the first dogs ...
(Date:4/29/2015)... 2015 /CNW/ - Northern Biologics Inc., a privately held ... an exclusive, strategic collaboration with Celgene Corporation.  As ... US$30 million upfront cash payment. It will use ... antibodies, and will have the right to receive ... its portfolio. Under the agreement, ...
Breaking Biology Technology:Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2Northern Biologics and Celgene Enter Strategic Collaboration 2
... Nektar Therapeutics,(Nasdaq: NKTR ) announced today that ... NKTR-102 in platinum-resistant ovarian cancer. Regulatory approvals,have also ... additional,trials: a randomized Phase 2 study to evaluate NKTR-102 ... gene mutation, and a,Phase 2 study in metastatic breast ...
... - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ... has been granted its 31st U.S. Patent, # ... The patent includes claims to pharmaceutical compositions containing ... our proprietary position for REOLYSIN(R)," said Mary Ann ...
... Support Development of Micromet,s EpCAM-specific Antibody Therapeutics BETHESDA, ... (Nasdaq: MITI ), a biopharmaceutical company ... cancer, inflammation and autoimmune diseases today announced the ... Nature Cell Biology (1) revealing a novel ...
Cached Biology Technology:First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 2First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 3First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 4Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent 2Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling 2Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling 3Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling 4
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... at high latitudes grow better than their counterparts closer ... The study, published in the February issue of The ... Bergmann,s Rule, the observation that animals tend to be ... Bergmann made his observation about latitude and size in ...
... Centers for Disease Control and Prevention, the U.S. Food and ... and Inspection Service are investigating a multistate outbreak of Salmonella ... University of Iowa confirmed on Monday, Jan. 25, that this ... sickened 187 people in 39 states (one case in Iowa) ...
... Professor of Philosophy at Stevens Institute of Technology, was recently ... 2009 in History of Science by the History of Science ... Letters at Stevens, was co-author of the paper, "After the ... wrote the paper with Angela N. H. Creager, a Professor ...
Cached Biology News:Better food makes high-latitude animals bigger 2Hygienic Lab at U. Iowa first to confirm salmonella in nationwide outbreak 2
KNP-1 (HES1) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 35, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
... E978 GenBank Accession ... Immunogen : NY-ESO-1 full-length ... ascites with 0.05% sodium ... evaluated by immunoblot on ...
NATIVE RAT OSTEOCALCIN...
Form: Ready to use Applications: Immunohistology-frozen, Immunohistology-paraffin, Western Blot, ELISA...
Biology Products: